|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.
The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 179.19% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Celyad Oncology (NASDAQ: CYAD) is $3.94 last updated Fri Jan 21 2022 21:00:03 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Celyad Oncology.
Celyad Oncology’s $FY earnings are confirmed for after-market on April 9, 2022.
There is no upcoming split for Celyad Oncology.
Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.